www.terrapinn.com/stemcellsusa

Stem Cells & Regenerative Medicine Congress

Top 20 up-and-coming cell and gene therapy influencers
Top 20 up-and-coming cell and gene therapy influencers

In a growing and rapidly developing stem cells, cell and gene therapy industry, more and more companies are starting to shine and present impressive data for promising upcoming approved therapies. The rise of these biotech companies is in great part due to their executive leadership teams.

A few years ago there were just a few companies that could be considered promising in the cell and gene therapy space with a next-to-launch status. But, today more and more companies have been emerging with promising approaches and cell and gene therapies under development.

The top 20 up-and-coming cell and gene therapy influencers contributing to this trend are highlighted in this report.
Selection criteria

This ranking was built based on research conducted with leading and emerging companies working in the stem cells, cell and gene therapies space, as well as regulators, patient groups and academic institutions.

The selection criteria included:

• Recent increased clinical attrition
• The ability to deploy capital formation strategies
• Published studies
• Awareness across different markets
• Personal recognition

Did we miss anyone? Let us know – I value your feedback!
20. Geoff Crouse, CEO, Cord Blood Registry

With cord blood banks around the world shifting business models in today’s business environment, Geoff has been leading the largest cord blood bank towards also becoming a renowned cell therapy center.

About Geoff:

Geoff Crouse joined CBR as CEO in September 2012. He previously served as Chief Operating Officer at Immucor, a publicly traded global in vitro diagnostics company that was sold to TPG in 2011. Prior to Immucor, he served as vice president of the life sciences business at Millipore Corporation, a NYSE-traded provider of technologies, tools and services for the global life science industry. In this role, he led the Life Science Strategic Business Unit, a global laboratory consumables and reagents business. Prior to joining Millipore, he worked at Roche, a leader in the pharmaceuticals and diagnostics industries, where he led market development and government affairs for the diagnostics division based in Basel, Switzerland. Mr. Crouse earned a B.A. from Boston College and an M.B.A. and Masters of Public Health from the University of California at Berkeley.
19. **David Eller, Chairman & CEO, Celltex Therapeutics**

David is behind Celltex’s innovative approach to become one of the most renowned stem cells companies focused on autologous therapies. He has led the company in its strategy to establish strong collaborations in Mexico to advance stem cells treatments.

**About David:**

David Eller is a graduate of Texas A&M University, the Stanford Graduate School of Business Executive Program, the Harvard Business School Advanced Management Program, and the Stanford Business School Corporate Governance Program. He also served eight years as officer on active duty and reserves for the United States Army, Corps of Engineers. He served as a Commanding Officer, 541st Combat Engineer Company, 11th Engineer Group, 7th Army, Corps of Engineers – Schwetzingen, Germany.

Mr. Eller has a career in senior management which spans 35 years. His positions during this time include President of DuPont Pharmaceuticals Company – Europe, Strategic Advisor to the Chief Operating Officer of the E. I. du Pont de Nemours and Company (“The DuPont Company”); Chief Executive Officer and President of Virbac Corporation; and Founder, Chairman, and Chief Executive Officer of Granada Biosciences, Inc. Along with these prestigious positions, Mr. Eller has also provided consulting services to many public and privately held domestic and international corporations which operate in different industry sectors. These industries range from life sciences and bioscience research and development to pharmaceutical manufacturing and distribution.

In addition to many positions in his senior management career, Mr. Eller has served two terms as Chairman of the Board of Regents of the Texas A&M University System, while concurrently serving as Chancellor of the Texas A&M University System for a short period. During his tenure at Texas A&M University, Mr. Eller established the Institute of Biosciences and Technology, which is located in the Texas Medical Center. He also established a number of additional bioscience programs which included establishing procedures for intellectual property commercialization.
Dr. Brentjens has been an important advocate of the value of small studies to advance the development of new cell-based therapies. His recent study on a treatment that genetically alters a patient’s own immune cells to fight cancer has, for the first time, produced remissions in adults with an acute leukemia that is usually lethal.

About Renier:

Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen. These latter projects are similarly in the process of translation to the clinical setting.
17. Enrico Bastianelli, CEO, Bone Therapeutics

Under Enrico’s leadership, Bone Therapeutics has been awarded with ‘Tissue Establishment’ and ‘GMP’ accreditation for the manufacture of its allogeneic bone cell therapy product, initially developed for the treatment of non-union fractures. He has also led the company’s investment in Skeletal Cell Therapy Support S.A (SCTS) to fund the construction of a new state-of-the-art manufacturing facility based in the Gosselies Scientific Park near Brussels, Belgium.

About Enrico:

Dr. Bastianelli has a long standing experience in pharmaceutical industry in fields as broad as Sales & Marketing, R&D, Licensing, Corporate Development and Strategy. His career started in the Pathology Department of the Erasme University Hospital in Belgium. Then he joined Procter & Gamble Pharmaceuticals in 1996, where he was involved in the marketing of ethical and over-the-counter drugs in the field of bone diseases. In 1999, he became a Consultant for McKinsey & Co, where he was involved in strategic and organizational missions for major pharmaceutical as well as biotechnology companies all over Europe. From its creation in 2002 until mid-2006, Dr. Bastianelli worked as VP Corporate Development for ProSkelia, spin-out of Aventis focused on bone diseases and hormone disorders (which then became ProStrakan, after the merger with Strakan, a Scottish pharmaceutical company). As a member of the Executive Committee, he was responsible for the management of the R&D portfolio, resources allocation and planning, alliances, collaborations and downstream integration. He was one of the main contributors to the merger with Strakan.

Since June 2006, he is Chief Executive Officer of Bone Therapeutics.
16. Christian Homsy, CEO, Cardio3 BioSciences

Christian could not be left out of this ranking, as his wide experience in the cell therapy space has led C3BS to very promising data results from a Phase II randomized trial for a therapy that repairs heart failure. The company is conducting a Phase III trial in Belgium and the UK, and they had their first patient enrolled last month. Their technology consists of reprogramming stem cells into cardiac lineage before injecting them into the heart.

About Christian:

Christian Homsy, Chief Executive Officer (CEO) of Cardio3 BioSciences and Member of the Board as Executive Director – Christian Homsy obtained his Medical Doctorate at the University of Louvain and holds an MBA from the IMD in Lausanne (Switzerland). He has been Chief Executive Officer (CEO) of Cardio3 BioSciences since its foundation. Christian gained his business experience in senior research and development, marketing, business development and sales positions at Guidant Corporation, a leading medical device company active in the treatment of cardiovascular disease. He was also founder of Guidant Institute for Therapy Development, a landmark facility for physician and health care professionals' education that gained international recognition and praise. Christian excelled in building businesses with well respected teams, setting standards inside and outside the organization. Before joining Cardio3 BioSciences, Christian Homsy was General Manager of Medpole, a European incubator dedicated to initiating the European operations for start-up companies in the medical device or biotechnology fields. He also holds a director mandate in Medpole SA.
15. Yael Margolin, President & CEO, Gamida Cell

When companies like Israeli Gamida Cell publishes such promising studies on technologies like NiCord® and StemEx® it’s essential to grant their leadership a high-level of recognition. Yael had led the company to conduct a multi-center, multi-national, historic cohort-controlled study to evaluate efficacy and safety of StemEx® as an alternative transplantation treatment for patients with high risk leukemia and lymphoma.

About Yael:

Dr. Margolin is the president and CEO of Gamida Cell. Prior to joining the company, Dr. Margolin served as vice president of Denali Ventures LLC, where she specialized in investments in pharmaceutical and biotechnology companies. Dr. Margolin also worked at Teva Pharmaceuticals, where she was responsible for new product initiatives, evaluation of investment opportunities for the R&D division, and multiple drug development programs. Dr. Margolin holds a Ph.D. in Biology from the Weizmann Institute of Science and was a post-doctoral associate at the Yale University School of Medicine.
Ram has led the funding initiatives of Cellerant, allowing the company to close a deal with BARDA for a five-year award valued of up to $169.9 million. The additional funding will continue to support Cellerant's CLT-008 development strategy by providing funds for its ongoing clinical trials, process development and manufacturing activities and the nonclinical studies required for approval in ARS.

About Ram:

Ram Mandalam, Ph.D. joined the company in 2005. Ram was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.
13. Gary Rabin, Chairman & CEO, Advanced Cell Technology

Gary has been at the helm of one of the most exciting new generation stem cell biotechs out there today, Advanced Cell Technology. ACT’s two ES cell-based FDA-approved clinical trials have shown quite promising preliminary safety data and the company holds an impressive pipeline including potentially iPS cell-related products such as platelets.

About Gary:

Gary Rabin’s 25-year career in finance and operations has primarily encompassed investing in, managing and raising capital for small-cap and emerging growth companies. From 2007 to 2010, he was Managing Partner at GR Advisors, LLC, a hedge fund focused on media and communications. From 2005 to 2007, he was a Portfolio Manager at MACInvestment Management, LLC (“MAC”), a hedge fund concentrating on technology, communications and healthcare. Prior to that he was a Managing Director and Portfolio Manager at Marketus Associates, a hedge fund focused on communications, healthcare services and energy. Before that, he was Managing Director and Co-Head of the Media and Telecom Investment Banking Group at CIBC World Markets (“CIBC”), where he was responsible for all corporate finance and M&A, financial restructurings and principal investing activities (both debt and equity) within the sector. Before joining CIBC, Mr. Rabin served as Chief Strategy Officer of CAIS Internet, Inc. (“CAIS”), a broadband services company, where he was responsible for securing over $500 million in financing commitments. Mr. Rabin has also served as Managing Director and Head of the Global Telecom Investment Banking Group at ING Barings Furman Selz and was a founder of the telecom group at UBS Securities. He began his career in finance in 1987 and concentrated on energy, utilities and metals until 1993. Mr. Rabin earned an AB in Economics from the University of Michigan.
12. Robin Smith, Chairman & CEO, NeoStem

During her tenure over the past six years as Chairman and CEO, Dr. Smith has successfully led NeoStem to complete five acquisitions and raise over 100 million dollars toward building a leading company in the emerging cell therapy industry.

About Robin:

Dr. Robin L. Smith became the Chief Executive Officer and Chairman of the Board of NeoStem effective June 2, 2006, after first joining the Company as Chairman of its Advisory Board in September 2005. Dr. Smith brings to NeoStem expertise in business development and medicine, including her extensive and diversified experience serving in executive and board capacities in medical enterprises and healthcare-based entities.

From 2000 to 2003, Dr. Smith served as President & Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston. IP2M was sold to a publicly-traded company in February 2003. Previously, from 1998 to 2000, she was Executive Vice President and Chief Medical Officer for HealthHelp, Inc., a National Radiology Management company that managed 14 percent of the healthcare dollars spent by large insurance companies.

Dr. Smith has acted as a senior advisor to, and investor in, both publicly traded and privately held companies where she has played a significant role in restructuring and or growing the companies. She currently serves on the Board of Trustees of the NYU Medical Center Board, is past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases where she headed up new development efforts and board member recruitment, and served on the Board of Choose Living. Dr. Smith is the President and serves on the Board of Directors of The Stem for Life Foundation. Dr. Smith received a medical degree from Yale University in 1992 and a master’s degree in business administration from the Wharton School in 1997.
11. Zami Aberman, President & CEO, Pluristem

Mr. Aberman changed Pluristem’s strategy towards cellular therapeutics by sticking to his vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy. This, combined with the company’s 3D culturing technology, has positioned Pluristem as a worldwide recognized stem cell company.

About Zami:

Mr. Aberman has 20 years of experience in marketing and management in the high technology industry. He has held positions of Chief Executive Officer and Chairman in Israel, the USA, Europe, Japan and Korea. He has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company; He has served in the past as the Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a Director of Ori Software Ltd., a company involved in data management. Prior to that, he served as the President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronic industry.

In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel.

Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.
Keith Thompson, CEO, Cell Therapy Catapult

Keith has been leading Cell Therapy’s unique approach to foster innovation and strengthen the UK’s cell therapy industry. The first example of this successful initiative is the organization’s recent collaboration with ReNeuron, a UK-based cell therapy company. According to Keith, many more partnerships to come in the next year will provide high-level knowledge, manufacturing expertise and technologies and capital to ‘catapult’ the segment.

About Keith:

Keith Thompson was appointed Chief Executive of the Cell Therapy Catapult, part of a Technology Strategy Board initiative to improve UK economic capability by bridging the gap between academic invention and commercialisation, in May 2012.

Keith joined the Catapult from the Scottish National Blood Transfusion Service where he was National Director, focusing on modernising the blood supply, and expanding the service into cell therapy. Prior to this, Keith held various senior domestic and international positions where he grew several biomanufacturing businesses to become global players.
9. Michael May, CEO, Center for Commercialization of Regenerative Medicine

Michael heads one of the most innovative organizations in the regenerative medicine industry. CCRM mobilizes business and scientific expertise to translate RM and stem cell-based medical discoveries into commercial products and therapies. Their industry consortium addresses real-life bottlenecks in companies’ stem cell-based product pipelines by providing critical expertise, experience and market-pull information for the development of innovative RM technologies.

About Michael:

Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as a NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.

Michael is currently the Chief Executive Officer of CCRM. Prior to CCRM, Michael was the President, Chief Operating Officer and co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Michael sits on a number of Boards and advisory committees, including: MaRS Innovation, Rimon Therapeutics Ltd., 20/20 Vision, the Advanced Regenerative Tissue Engineering Centre, the Department of Chemical Engineering and Applied Chemistry, at the University of Toronto and the McMaster Mohawk Biotechnology Program.
8. Michael Hunt, CEO, ReNeuron

With an impressive business-led approach, Michael has been leading ReNeuron in its move to be the first company to get approval of a therapy for regeneration of disabilities caused by strokes. The company will be presenting encouraging data of its early stage trials conducted in the UK, and the partnership with Cell Therapy Catapult will allow the company to excel in getting its potential therapy to the market.

About Michael:

Michael Hunt joined ReNeuron as Chief Financial Officer in September 2003 and Chief Executive Officer in July 2005. Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He is a founding member and co-chair of the European Alliance for Advanced Therapies and sits on the BioIndustry Association’s Cell Therapy and Regenerative Medicine Advisory Committee and its Finance and Tax Advisory Committee. He is a past Senior Industry Group member of the UK Government’s Office for Life Sciences, a member of the UK Technology Strategy Board’s RegenMed Advisory Group and a member of the TSB’s Cell Therapy Catapult Interim Advisory Group. He read economics at University College London and qualified as a chartered accountant with Ernst & Young.
7. Christopher Calhoun, CEO, Cytori

Chris has given Cytori considerable momentum for a recent two-year deal with the Department of Health and Human Service’s Biomedical Advanced Research and Development Authority, which may be worth $106 million over five years if certain milestones are met.

About Christopher:

Christopher J. Calhoun is a co-founder of Cytori Therapeutics and has served as the company's Chief Executive Officer, Vice-Chairman and Director of the board since 1997. He previously served as President from 1996 through 1998. Mr. Calhoun is the co-inventor on multiple U.S. and international patents for medical devices and implant instrumentation. Mr. Calhoun was also involved in research and management for the plastic surgery bone histology and histometry laboratory at the University of California, San Diego. Mr. Calhoun is a Co-Founder and Chairman of the board of Leonardo MD, and has previously served on the board of directors of Stemsource, Inc. Mr. Calhoun received a B.A. from the University of California, San Diego and an M.B.A. from the University of Phoenix.
6. Mitchell Seyedin, President & CEO, ISTO Technologies

For the past 10 years, Mitch has been leading one of the few companies with a cell-based orthobiologic platform for growing cartilage tissues for number of applications. The company is currently involved in the development of two unique and potentially ground-breaking cell-based products intended to treat two of the leading causes of disability in the United States.

About Mitchell:

Mitchell Seyedin, Ph.D., joined ISTO in September 2003. Before joining ISTO Technologies, Dr. Seyedin served as President and CEO of CBYON Inc., which developed and marketed advanced image-guided surgical systems. In 1995, he founded Orquest, an orthobiologic company that developed biological products for orthopedic applications. He served as its CEO for the first two years, as its Chairman until October 2001, and as a Board member until its acquisition by Johnson & Johnson in January 2003. In 1990, Dr. Seyedin co-founded Metra Biosystems and served as Vice President of Research & Development. Metra developed and commercialized diagnostic tests for osteoporosis and cancer. In 1995, Metra went public and was later acquired by Quidel (NASDAQ:QDEL) in June 1999. Before founding Metra, Dr. Seyedin was the Director of Research at Collagen Corporation, where he was responsible for bone and cartilage research. Currently, he serves on the Board of Directors of BioSet Inc., a privately held biotechnology company. Dr. Seyedin holds a B.S. in Chemistry from the University of Wisconsin, a Ph.D. in Biochemistry from the University of South Carolina and completed his post-doctoral training at the University of California - Berkeley.
JJ Finkelstein has served as President and Chief Executive Officer and a member of the Board of Directors since 2002. Mr. Finkelstein also served as Chief Executive Officer from 1984 to 1989 and as the Vice Chairman of the Board of Directors from 1989 to 1991. Mr. Finkelstein has worked as an executive officer and consultant in the bioscience industry for the past 30 years, including serving from 1989 to 1996 as chief executive officer of Cryomedical Sciences, Inc., a publicly-traded medical device company. Mr. Finkelstein has significant experience in developing early-stage companies. He has been responsible for the regulatory approval and marketing of several medical devices in the U.S. and abroad. Mr. Finkelstein has served on the executive committee of the Board of Directors of the Technology Council of Maryland since 2006, MdBio, Inc. since 1998 and currently chairs the MdBio Foundation, all of which are non-profit entities that support bioscience development and education in the State of Maryland. Mr. Finkelstein received a business degree in finance from the University of Texas. The Board believes that Mr. Finkelstein’s history and long tenure as our Chief Executive Officer positions him to contribute to the Board his extensive knowledge of the company and to provide Board continuity. In addition, the Board believes that his experience at prior companies has provided him with operational and industry expertise, as well as leadership skills that are important to the Board.
4. Paul Laikind, President, Viacyte

Potentially known across the global stem cells community, Paul is behind Viacyte’s success with one of the most advanced stem cell derived, cell therapy for patients with insulin-dependent diabetes. The company’s comprehensive and growing intellectual property portfolio and their platform technology with multiple important applications are some of the factors positioning Viacyte at the top.

About Paul:

Paul K. Laikind, Ph.D. has over 25 years of leadership experience in the biotechnology and life sciences industry in San Diego. A serial entrepreneur, Dr. Laikind co-founded and held top executive positions at three San Diego companies that each went public before ultimately being acquired. These include Gensia Pharmaceuticals, Inc., Viagene, Inc., which, like Gensia, was founded upon technology Dr. Laikind helped to create, and, most recently, Metabasis Therapeutics, Inc. where he served as President and Chief Executive Officer. Just prior to joining ViaCyte, Dr. Laikind served as Chief Business Officer and Senior Vice President of Business Development at the Sanford-Burnham Medical Research Institute where he established a number of licensing and strategic partnerships with large pharmaceutical organizations, including collaborations with Pfizer’s Centers for Therapeutic Innovation, Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Takeda Pharmaceutical. Dr. Laikind holds a B.S. in Biochemistry from the University of California, Davis, and a Ph.D. in biochemistry from the University of California, San Diego.
3. Gail Naughton, Chairman & CEO, Histogen

Gail founded Histogen, Inc. in 2007, and has spent more than 25 years extensively researching the tissue engineering process, holds more than 95 U.S. and foreign patents, and has been extensively published in the field. With a successful aesthetics strategy, Gail has allowed Histogen to advance the development of innovative therapies based upon the products of cells grown under simulated embryonic conditions.

About Gail:

During her tenure at Advanced Tissue Sciences, where she was the company’s co-founder and co-inventor of its core technology, Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch.

In addition to this work, Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011, where she helped to make SDSU the first campus in the nation to found a Ph.D./MBA in life sciences. In 2000, Dr. Naughton received the National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. She sits on the Board of directors of the CR Bard (NYSE: BCR) and the La Jolla Institute for Allergy and Immunology, as well as in the Advisory Board of Georgia Tech, the Ackerman Foundation, and Perminova.

Dr. Naughton earned her B.S. in biology from St. Francis College and her Ph.D. in Basic Medical Sciences and her M.S. in histology from the New York University Medical Center. She earned an executive MBA in 2001 from the Anderson School at the University of California, Los Angeles.
2. Jeffrey Abbey, President & CEO, Argos Therapeutics

When Argos announced it would withdraw its IPO, Jeff Abbey had a clear goal in his mind. Betting on the company’s upcoming successful phase III clinical data for the company’s kidney cancer candidate, Jeff understood the investors’ rationale and opted for waiting to get final data before going public. This is why Jeff made this list at number 2.

About Jeff:

Jeffrey Abbey joined Argos Therapeutics in 2002. Before joining Argos, Mr. Abbey was Vice President of Business Development and Finance for Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a partner in Eilenberg and Krause, a boutique corporate law firm, where he acted as business counsel for a number of life sciences and other emerging technology companies. Mr. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. He holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.
1. Richard Garr, President, Neuralstem

Nowadays, Richard needs no formal introductions. He’s well known for leading Neuralstem’s patented technology, which enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities. Recent early stage clinical data has excited the entire stem cells community in regards potential approved therapies in the neurological field.

About Richard:

Richard Garr, J.D. has been Neuralstem’s Chief Executive Officer, President and Director since 1996. He is serving as the interim Chief Financial Officer, due to the retirement in April 2012 of the company’s CFO. Mr. Garr has extensive corporate legal, regulatory and patent experience and has focused on the business of science for 16 years. He was previously an attorney with Beli, Weil & Jacobs, the B&G Companies, and Circle Management Companies. Mr. Garr is a graduate of Drew University (1976) and the Columbus School of Law, The Catholic University of America (1979). Additionally, he is a founder and current Board member of the First Star Foundation, a children’s charity focused on abused children’s issues; a founder of The Starlight Foundation Mid Atlantic chapter, which focuses on helping seriously ill children; and a past Honorary Chairman of the Brain Tumor Society.
We’d love to hear your views on all of this...

Join the conversation

- Click here to view our YouTube channel
- Click here to contribute to our LinkedIn discussion
- Click here to follow us on Twitter @TotalBiopharma #StemCellsUSA
- Click here check out our Total Biopharma blog, for more updates on orphan drugs, rare diseases and more

www.terrapinn.com/stemcellsusa
We’d love to meet you too...

We’re hosting Stem Cells & Regenerative Medicine Congress 2013 this September and would love to see you there.

The event will be co-located with World Cord Blood Congress and Cell Culture World Congress USA.

Hear from pharma, biotechs, academia and government as they discuss:

• How to optimize clinical development of stem cell therapies
• How to overcome strategic and regulatory challenges
• How to negotiate reimbursement
• How to navigate funding and partnership opportunities
• How to implement stem cell platforms into drug discovery

Interested in sponsorship, exhibition or speaking opportunities? Contact me, Andre, at +1 646 619 1797 or email me at andre.singer@terrapinn.com for more information.